Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment. This latest product is bioequivalent and therapeutically equivalent to Xalatan® Ophthalmic Solution, 0.005% of Upjohn US 2 LLC.

According to IQVIA sales data for the 12-month period ending December 2024, the market for Xalatan® Ophthalmic Solution, 0.005% recorded annual sales of approximately $113.5 million. Glenmark's entry into this space is expected to provide a cost-effective alternative while expanding treatment options for patients.

Marc Kikuchi, President & Business Head, North America, expressed enthusiasm about this launch, stating, “We are excited to announce the launch of our fourth ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”

Image Source: InvestingPro+

Beyond its product expansion, Glenmark Pharmaceuticals Limited presents an attractive investment case. According to InvestingPro’s fair value feature, the company’s intrinsic value is estimated at INR 1533.5 per share, implying a 14.8% upside from the current market price (CMP) of INR 1335. This valuation suggests that Glenmark's stock remains undervalued despite its ongoing growth initiatives.

Investors leveraging InvestingPro's valuation tools would have recognized this potential, making data-backed investment decisions to capitalize on Glenmark’s growth trajectory. By providing real-time fair value estimates based on multiple financial models, InvestingPro ensures investors have access to precise and actionable insights.

InvestingPro empowers investors with cutting-edge stock analysis tools, helping them assess fair values and identify investment opportunities. With the platform currently offering discounts of up to 45% on subscriptions, now is the ideal time for investors to gain access to its comprehensive valuation insights and market intelligence.

Read More: 12X Your Returns? How “Bharat Bargains Strategy” Crushed the Market

X (formerly, Twitter) - Aayush Khanna

LinkedIn - Aayush Khanna